405 related articles for article (PubMed ID: 32533433)
41. Safety signal detection and evaluation in clinical development programs: A case study of tofacitinib.
Dasic G; Jones T; Frajzyngier V; Rojo R; Madsen A; Valdez H
Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417755
[TBL] [Abstract][Full Text] [Related]
42. Analysis of the association between Janus kinase inhibitors and malignant skin tumors using the Food and Drug Administration Adverse Event Reporting System.
Liu T; Gao R; Li L; Wu B; Wu F
Int J Clin Pharm; 2023 Dec; 45(6):1483-1491. PubMed ID: 37606843
[TBL] [Abstract][Full Text] [Related]
43. The safety of baricitinib in patients with rheumatoid arthritis.
Honda S; Harigai M
Expert Opin Drug Saf; 2020 May; 19(5):545-551. PubMed ID: 32174196
[No Abstract] [Full Text] [Related]
44. Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison.
Fautrel B; Zhu B; Taylor PC; van de Laar M; Emery P; De Leonardis F; Kannowski CL; Nicolay C; Kadziola Z; De La Torre I; Fleischmann R
RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371431
[TBL] [Abstract][Full Text] [Related]
45. JAK inhibitors and risk of major cardiovascular events or venous thromboembolism: a self-controlled case series study.
Gouverneur A; Avouac J; Prati C; Cracowski JL; Schaeverbeke T; Pariente A; Truchetet ME
Eur J Clin Pharmacol; 2022 Dec; 78(12):1981-1990. PubMed ID: 36284012
[TBL] [Abstract][Full Text] [Related]
46. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
[TBL] [Abstract][Full Text] [Related]
47. Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?
Harigai M; Honda S
Drugs; 2020 Aug; 80(12):1183-1201. PubMed ID: 32681420
[TBL] [Abstract][Full Text] [Related]
48. Conversion of Functional Assessment of Chronic Illness Therapy-Fatigue to Patient-Reported Outcomes Measurement Information System Fatigue Scores in Two Phase III Baricitinib Rheumatoid Arthritis Trials.
Bingham CO; Bartlett SJ; Kannowski C; Sun L; DeLozier AM; Cella D
Arthritis Care Res (Hoboken); 2021 Apr; 73(4):481-488. PubMed ID: 31961494
[TBL] [Abstract][Full Text] [Related]
49. JAK inhibitors in the treatment of adult patients with juvenile idiopathic arthritis: a retrospective monocentric experience.
Chighizola CB; Pellico MR; Pandolfi M; Marelli L; Cornalba M; Pontikaki I; Costi S; Gattinara M; Marino A; Miserocchi E; Caporali R
Clin Exp Rheumatol; 2024 May; 42(5):974-982. PubMed ID: 38530666
[TBL] [Abstract][Full Text] [Related]
50. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
[TBL] [Abstract][Full Text] [Related]
51. JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells.
Fujita Y; Matsuoka N; Temmoku J; Furuya-Yashiro M; Asano T; Sato S; Matsumoto H; Watanabe H; Kozuru H; Yatsuhashi H; Kawakami A; Migita K
BMC Immunol; 2020 Jun; 21(1):35. PubMed ID: 32539713
[TBL] [Abstract][Full Text] [Related]
52. Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study.
Desai RJ; Pawar A; Khosrow-Khavar F; Weinblatt ME; Kim SC
Rheumatology (Oxford); 2021 Dec; 61(1):121-130. PubMed ID: 33752237
[TBL] [Abstract][Full Text] [Related]
53. Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.
Yates M; Mootoo A; Adas M; Bechman K; Rampes S; Patel V; Qureshi S; Cope AP; Norton S; Galloway JB
Arthritis Rheumatol; 2021 May; 73(5):779-788. PubMed ID: 33174384
[TBL] [Abstract][Full Text] [Related]
54. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.
McInnes IB; Byers NL; Higgs RE; Lee J; Macias WL; Na S; Ortmann RA; Rocha G; Rooney TP; Wehrman T; Zhang X; Zuckerman SH; Taylor PC
Arthritis Res Ther; 2019 Aug; 21(1):183. PubMed ID: 31375130
[TBL] [Abstract][Full Text] [Related]
55. Two new drugs for rheumatoid arthritis.
Drug Ther Bull; 2017 Sep; 55(9):102-105. PubMed ID: 28882850
[TBL] [Abstract][Full Text] [Related]
56. Skin cancers under Janus kinase inhibitors: A World Health Organization drug safety database analysis.
Jalles C; Lepelley M; Mouret S; Charles J; Leccia MT; Trabelsi S
Therapie; 2022; 77(6):649-656. PubMed ID: 35710462
[TBL] [Abstract][Full Text] [Related]
57. Physiologically-Based Pharmacokinetic Modelling to Investigate Baricitinib and Tofacitinib Dosing Recommendations for COVID-19 in Geriatrics.
Wang Z; Chan ECY
Clin Pharmacol Ther; 2022 Aug; 112(2):291-296. PubMed ID: 35380176
[TBL] [Abstract][Full Text] [Related]
58. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.
Sandborn WJ; Panés J; Sands BE; Reinisch W; Su C; Lawendy N; Koram N; Fan H; Jones TV; Modesto I; Quirk D; Danese S
Aliment Pharmacol Ther; 2019 Nov; 50(10):1068-1076. PubMed ID: 31599001
[TBL] [Abstract][Full Text] [Related]
59. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
[TBL] [Abstract][Full Text] [Related]
60. Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis.
Mogul A; Corsi K; McAuliffe L
Ann Pharmacother; 2019 Sep; 53(9):947-953. PubMed ID: 30907116
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
